Characterization of immunoliposomes as delivery vehicles for the Rac inhibitor Ehop-016 in HER2 type breast cancer

被引：0
|
作者：
Rivera-Robles, Michael J.
Vivas-Mejia, Pablo E.
Castillo-Pichardo, Linette
Vlaar, Cornelis
Hernandez, Eliud
Dharmawardhane, Suranganie
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2197
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2197
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models
    Hapuarachchige, Sudath
    Kato, Yoshinori
    Artemov, Dmitri
    SCIENTIFIC REPORTS, 2016, 6
  • [42] Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib, with HER2 Specific Cytotoxic T-Lymphocytes in the Treatment of HER2 Overexpressing Breast Cancer
    Agrawal, Vaibhav
    Brown, Christine E.
    Aguilar, Brenda
    Starr, Renate
    Forman, Stephen J.
    Jensen, Michael C.
    MOLECULAR THERAPY, 2012, 20 : S77 - S77
  • [43] Preparation and Characterization of Novel SPECT Radioimmunoimaging Tracers for HER2 Expressing Breast Cancer
    Mithun, Sneha
    Jha, Ashish
    Nautiyal, Amit
    Mehta, Grace Monica S.
    Vilangattil, Meryl Maria
    Bhardwaj, Punita
    Chitnis, Kinnari
    Babu, Merline
    Nisar, Niha
    Chakraborty, Sayan
    Dighe, Pranjal
    Maniar, Jinesh
    Shah, Sneha
    Kameswaran, Mythili
    Gupta, Sudeep
    Rangarajan, Venkatesh
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [44] Characterization of low HER2 expressions in de-novo metastatic breast cancer
    Tarantino, P.
    Nicolo, E.
    Zagami, P.
    Giugliano, F.
    Aliaga, P. Trillo
    Crimini, E.
    Corti, C.
    Uliano, J.
    Morganti, S.
    Mazzarella, L.
    Criscitiello, C.
    Esposito, A.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S31 - S31
  • [45] HER2 immunohistochemical scores provide prognostic information for patients with HER2-type invasive breast cancer
    Tsai, Yi-Fang
    Tseng, Ling-Ming
    Lien, Pei-Ju
    Hsu, Chih-Yi
    Lin, Yen-Shu
    King, Kuang-Liang
    Wang, Yu-Ling
    Chao, Ta-Chung
    Liu, Chun-Yu
    Chiu, Jen-Hwey
    Yang, Muh-Hwa
    HISTOPATHOLOGY, 2019, 74 (04) : 578 - 586
  • [46] Targeting Rac/Cdc42 in human epidermal growth factor receptor 2 (HER2)-positive breast cancer
    Rivera-Robles, M. J.
    Medina-Vlazquez, J. I.
    Borrero-Garcia, L. D.
    Velazquez-Vega, L. E.
    Maldonado, Md M.
    Ruiz-Calderon, J.
    Castillo-Pichardo, L.
    Vivas-Mejia, P.
    Dharmawardhane, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [47] A novel HER2 inhibitor TAK-285 overcomes trastuzumab resistance of HER2-over-expressing breast cancer
    Hayashi, A.
    Tamura, T.
    Yusa, T.
    Takagi, S.
    Ohta, Y.
    CANCER RESEARCH, 2009, 69 (02) : 245S - 245S
  • [48] Inhibitor Response to HER2 G776YVMA In-frame Insertion in HER2-positive Breast Cancer
    Zheng, Ya-Bing
    Yu, Yang
    Chen, Bo
    Hu, Jin-Lin
    Jing, Tian
    Zhang, Xi-Ping
    CANCER INVESTIGATION, 2016, 34 (03) : 123 - 129
  • [49] UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
    Hua, Jun
    Zhang, Zhe
    Zhang, Lili
    Sun, Yan
    Yuan, Yuan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (04) : 633 - 642
  • [50] Tandem peptides targeting HER2 for delivery of CD44 siRNA into HER2+breast cancer cells in vitro
    Kalogeros, James W.
    Miserendino, Audreanna
    Alexander-Bryant, Angela
    Booth, Brian
    CANCER RESEARCH, 2023, 83 (07)
12345